Zobrazeno 1 - 5
of 5
pro vyhledávání: '"June H-J Han"'
Autor:
Namkyeong Kim, Jung Hee Park, Ky-Youb Nam, June H-J Han, Kyu-Tae Kim, Sandip Sengupta, Jeong Hyeok Yoon, Taebo Sim
Publikováno v:
Cancer Research. 83:1627-1627
Background: PHI-501 has been developed as a novel inhibitor of NRAS mutated acute myeloid leukemia. Big data and artificial intelligence (AI)-based drug discovery platform and cell-based investigation identified PHI-501 repurposable against melanoma
Autor:
Sue Min Kim, Jung Hee Park, Ky-Youb Nam, June H-J Han, Kyu-Tae Kim, Jeong Hyeok Yoon, Sandip Sengupta, Taebo Sim, Sang Joon Shin
Publikováno v:
Cancer Research. 83:411-411
Background: PHI-501 is a newly developed, highly effective, and orally accessible dual inhibitor for pan-RAF and discoidin domain receptor (DDR) that is a collagen-activated receptor tyrosine kinase. Mutations of the BRAF and NRAS are the most common
Autor:
Ky-Youb Nam, Jung Hee Park, Kyung Ah Kim, Inje Shin, June H-J Han, Kyu-Tae Kim, Jeong Hyeok Yoon, Hanna Cho, Seung-Hye Choi, Sandip Sengupta, Taebo Sim
Publikováno v:
Cancer Research. 82:5495-5495
Purpose: Development of the first-in-class inhibitor of NRAS mutated acute myeloid leukemia. PHI-501 has potent activity against receptor tyrosine kinases and intracellular kinases related to STAT, AKT, and ERK signaling. Description: Preclinical tes
Autor:
Bao Nguyen, Jeong-Hyeok Yoon, Yunsuk Choi, Joseph Clarey, Ky-Youb Nam, Ho-Jin Shin, Jeong Ok Lee, Anish Puliyayil, Jeejin Im, Jun Ho Jang, Kyu-Tae Kim, Dong-Yeop Shin, Sung-Soo Yoon, June-Won Cheong, June H-J. Han, Je-Hwan Lee, Donald Small, Li Li
Publikováno v:
Blood. 138:3425-3425
Background: The FMS-like tyrosine kinase 3 (FLT3) is mutated in approximately 30% of acute myeloid leukemia (AML) patients either by internal tandem duplication (ITD) or by point mutations in the tyrosine kinase domain (TKD). PHI-101 is a Type I FLT3
Autor:
Kyu-Tae Kim, Jeejin Im, Min Kyung Choi, Ky-Youb Nam, Jeong-Hyeok Yoon, Inki Kim, Sojung Park, June H-J. Han
Publikováno v:
Cancer Research. 81:1461-1461
Purpose: Development of the potent and selective checkpoint kinase 2 (CHK2) inhibitor to overcome limiting clinical utility of poly(ADP-ribose) polymerase 1 (PARP1) inhibitors. Experimental Procedure: Preclinical evaluation of PHI-101 for cellular an